A

argenx SE
D

ARGX

623.96
USD
-2.19
(-0.35%)
مغلق
حجم التداول
9,842
الربح لكل سهم
0
العائد الربحي
-
P/E
-800
حجم السوق
37,310,482,501
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    4.190
    (2.44%)
    175.700 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GSK
    GSK
    0.155
    (0.46%)
    33.595 USD
    LLY
    LLY
    11.01
    (1.45%)
    768.44 USD
    NVS
    NVS
    0.340
    (0.35%)
    97.070 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    SNY
    SNY
    0.170
    (0.36%)
    47.700 USD
    المزيد
الأخبار

العنوان: argenx SE

القطاع: Healthcare
الصناعة: Biotechnology
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.